Immunization of newborns with bacterial conjugate vaccines.

Autor: van den Biggelaar AH; Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, PO Box 855, West Perth, WA 6872, Australia. Anita.vandenBiggelaar@Crucell.com, Pomat WS
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2013 May 17; Vol. 31 (21), pp. 2525-30. Date of Electronic Publication: 2012 Jun 19.
DOI: 10.1016/j.vaccine.2012.06.019
Abstrakt: Bacterial conjugate vaccines are based on the principle of coupling immunogenic bacterial capsular polysaccharides to a carrier protein to facilitate the induction of memory T-cell responses. Following the success of Haemophilus influenzae type b conjugate vaccines in the 1980s, conjugate vaccines for Streptococcus pneumoniae and Neisseria meningitidis infections were developed and proven to be effective in protecting children against invasive disease. In this review, the use of conjugate vaccines in human newborns is discussed. Neonatal Haemophilus influenzae type b and pneumococcal conjugate vaccination schedules have been trialed and proven to be safe, with the majority of studies demonstrating no evidence for the induction of immune tolerance. Whether their neonatal administration also results in an earlier induction of clinical protection in the first 2-3 critical months of life is still to be demonstrated.
(Copyright © 2012 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: